Growth priorities for medium pharma

The challenges facing drug developers have been well documented. Stories of dry pipelines and unhappy shareholders are common in the business press. This combined with increasing regulatory requirements, related escalating costs of development, and well publicised product withdrawals are leading those in the industry and its investors to wonder where future value can be realised.

Biotechnology has fed a number of products into the clinic for testing, and while many of these will not make it to market, there have been great successes (Genentech, Amgen, Biogen Idec, et al), and the sector continues to develop. An ageing population is putting an increasing burden on healthcare systems, this in turn creates opportunities for medicines to help alleviate pressure on hospital services.

The growing incidence of obesity, particularly in children, and the related increase in type 2 diabetes cases is a clear example of this situation. The requirement is for changes in lifestyle habits which may be underpinned by cessation type therapies.

New technologies in drug delivery, medical devices and medical imaging are continuing to challenge existing treatments for common diseases.

To find out more about the growth priorities for medium pharma, please contact us now